Welcome to our dedicated page for KIROMIC BIOPHARMA news (Ticker: KRBP), a resource for investors and traders seeking the latest updates and insights on KIROMIC BIOPHARMA stock.
Kiromic BioPharma Inc (KRBP) is a pioneering biopharmaceutical company dedicated to the development of advanced diagnostic and therapeutic solutions specifically targeting solid tumors and hematologic malignancies. Leveraging a robust portfolio of patented cancer-associated biomarkers and small molecules, Kiromic focuses on creating innovative clinical diagnostic tools and personalized immunotherapy strategies designed to improve patient outcomes, reduce suffering, and extend survival times.
Kiromic's core business revolves around its groundbreaking work in developing rapid detection mechanisms for cancer-associated antigens. This early detection capability can lead to earlier diagnoses and more accurate monitoring of patients' responses to treatments, potentially revolutionizing the field of cancer care. The company's cancer-associated biomarkers are instrumental in designing bespoke, cancer-specific targeted immunotherapies that promise higher efficacy and fewer side effects compared to traditional treatments.
Recent achievements by Kiromic BioPharma include significant advancements in their diagnostic and therapeutic programs. The company is actively engaged in several promising projects aimed at enhancing the precision and effectiveness of cancer treatments. Through strategic partnerships and collaborations, Kiromic continues to expand its research and development capabilities, constantly pushing the boundaries of cancer treatment innovation.
Financially, Kiromic BioPharma is committed to maintaining a stable and growing financial health, ensuring the sustainability of its ambitious projects and ongoing research. The company regularly updates stakeholders about its financial performance and significant milestones achieved, ensuring transparency and fostering investor confidence.
Noteworthy projects currently underway include the development of next-generation diagnostic tools that promise greater accuracy in detecting cancer-associated antigens, and the creation of more effective personalized immunotherapy treatments. By focusing on these critical areas, Kiromic aims to make substantial contributions to the field of oncology, offering hope and improved outcomes for cancer patients worldwide.
For the latest updates and relevant information about Kiromic BioPharma, including performance, events, and developments, investors and stakeholders are encouraged to follow the latest news releases.
Kiromic Biopharma (Nasdaq: KRBP) has announced the identification of new targets for solid tumor treatment using its AI-driven platforms, CancerDiff and Diamond AI. The targets include novel epitopes of NY-ESO-1 and a splice variant of Mesothelin, showing promise for CAR Gamma Delta T-cell therapy. Preclinical results were shared at the AACR meeting, highlighting the efficacy of these targets. Kiromic's AI distinguishes it in the immunotherapy field by significantly reducing the time and cost of biomarker identification, enhancing their drug discovery process.
Kiromic Biopharma (Nasdaq: KRBP) has submitted a novel IND to the FDA for a Phase 1 clinical trial of KB-PD1, a T-Cell therapy targeting PD-L1 in solid tumors. This therapy aims for improved efficacy and safety while lowering manufacturing costs. The ALEXIS-PRO-1 trial will include 30 patients with PD-L1 positive solid malignancies, with dosing expected by Q3 2021, pending FDA approval. Preliminary results showed rapid tumor elimination without toxicity, signifying potential advancements in cancer treatment.
Kiromic BioPharma (NASDAQ: KRBP) reported its quarterly results for the period ending March 31, 2021, achieving significant scientific milestones. The company plans to submit two IND applications to the FDA by May 2021 for its ALEXIS-PRO-1 and ALEXIS-ISO-1 therapies. Financial highlights include a cash position of $7.3 million, a net loss of $3.9 million, and an increase in R&D expenses by 83.41%. General and administrative expenses surged by 151.15% due to higher headcount and professional services.
Kiromic BioPharma (Nasdaq: KRBP) showcased its innovative technologies at the AACR 2021 meeting, highlighting their use of AI in developing CAR-T therapies for solid tumors. The company presented six posters on their proprietary platforms, including CancerDiff and CancerSplice, which harmonize large data sets for biomarker identification. Kiromic's AI-driven approach is believed to significantly lower development timelines compared to industry standards. The firm aims to lead in allogenic CAR-T therapies, expecting to realize this vision with planned human trials in Q3 2021.
Kiromic BioPharma (NASDAQ: KRBP) reported its financial results for 2020, highlighting significant milestones in drug development and corporate growth. The company enhanced its cash position to over $10 million following a successful IPO that raised $15 million. R&D expenses surged to $5 million, with a net loss of $19 million, up from $3.7 million in 2019. Kiromic plans to resubmit two IND applications for clinical trials focused on innovative CAR-T therapies. The company emphasizes its strategy using the DIAMOND AI platform to advance treatment efficacy in cancer.
Kiromic BioPharma (Nasdaq: KRBP) announced an interview with CEO Dr. Maurizio Chiriva-Internati, scheduled to air on The RedChip Money Report on Bloomberg Television on Saturday, March 27 at 7 p.m. local time. The interview will cover key topics including IND filing timelines, expanded indications, and GMP manufacturing updates. This segment reaches approximately 73 million homes, providing a platform for discussing Kiromic's immuno-oncology advancements and the proprietary Diamond AI platform that aids in oncology therapeutic development.
Kiromic Biopharma, Inc. (Nasdaq: KRBP) announced a planned resubmission of two investigational new drug (IND) applications to the FDA for its Allogenic Gamma-Delta T cell therapy targeting various solid tumors. Retaining 80% of the original protocols, the revised INDs aim for open enrollment, allowing broader eligibility across multiple cancers, enhancing potential market reach. Key changes include exclusively intravenous administration, streamlining procedures. The company expects IND resubmissions in 2Q 2021, with first-in-human dosing anticipated in 3Q 2021 and safety data by 4Q 2021.
Kiromic BioPharma, Inc. (Nasdaq: KRBP) has completed a licensing agreement for chPD1 with Longwood University, marking a significant milestone in CAR-T development. This innovative receptor not only inhibits the PD-1 pathway but also activates T-cell responses, potentially enhancing effectiveness against solid tumors. Kiromic's chimeric PD1 CAR-T aims to tackle challenges posed by the tumor micro-environment, positioning the company favorably for future clinical trials. Experts believe this advancement could distinguish Kiromic's offerings in the competitive CAR-T landscape.
Kiromic BioPharma (Nasdaq: KRBP) has completed and certified its GMP facility in Houston, Texas, meeting all FDA guidelines. This facility will support the company's upcoming first-in-human CAR-T trial targeting ovarian cancer. Key targets include chPD1 Gamma-Delta and anti-ISOMSLN. The Gamma-Delta-T cell GMP manufacturing test batch optimization is on schedule.
CEO Dr. Maurizio Chiriva-Internati emphasized that in-house manufacturing enhances trial efficiency. GDT cells, derived from healthy donors, promise to be more effective in targeting tumors compared to traditional T cells.
Kiromic Biopharma (Nasdaq: KRBP) has announced the filing of crucial European patents for its chimeric PD-1 (chPD1) target, focusing on immuno-oncology. The chPD1 receptor interacts with PD-1 ligands on various cancer cells, including those from ovarian and breast cancers, activating T-cells to destroy tumors. Preclinical data shows a 100% long-term progression-free survival rate in nine in vivo models. Kiromic's chPD1 will enhance their CAR-T therapy platform, led by Prof. Amorette Barber from Longwood University, aiming for significant advancements in cell therapies.
FAQ
What is the current stock price of KIROMIC BIOPHARMA (KRBP)?
What is the market cap of KIROMIC BIOPHARMA (KRBP)?
What does Kiromic BioPharma Inc do?
What are Kiromic's core areas of focus?
How does Kiromic's technology improve cancer treatment?
What recent achievements has Kiromic BioPharma made?
How does Kiromic ensure financial stability?
What projects are Kiromic currently working on?
Why are Kiromic's biomarkers important?
How can I stay updated on Kiromic's latest developments?
What is Kiromic's mission?
How does Kiromic contribute to oncology?
